CTLA4 and melanoma: Anti-CTLA-4 monoclonal antibody (tremelimumab and ipilimumab) has been found to block the interaction of CTLA-4 with CD80 and CD86, which may be used in the treatment of impaired cellular immunity in the course of viral infections and neoplastic diseases, e.g., melanoma [31,32].